A GLP-1/FGF21 Dual Agonist Slashed Liver Fat by 47% and Dropped HbA1c by 1.1% in Just 5 Weeks
HEC88473, a novel drug that combines GLP-1 and FGF21 activity, reduced liver fat by up to 47% and HbA1c by 1.1% in patients with fatty liver disease and type 2 diabetes after only 5 weeks of weekly injections.
Quick Facts
What This Study Found
HEC88473, a GLP-1/FGF21 dual agonist given as weekly subcutaneous injections for 5 weeks, produced dose-proportional reductions in liver fat measured by MRI-PDFF. The best-performing dose (30.6 mg) achieved a 47.21% relative reduction in liver fat (p = 0.0143) versus 15.05% with placebo. Patients with higher baseline fat (PDFF >8%) were more likely to achieve >30% relative reductions.
Blood sugar control also improved significantly: HbA1c dropped by up to 1.10% in the 68.0 mg group versus 0.31% with placebo, along with reductions in fasting and post-meal glucose levels. Lipid profiles improved across dose groups. The drug was generally well tolerated, with GI disorders being the most common adverse event (48.3%), mostly mild to moderate.
Key Numbers
n=60; liver fat ↓47.21% (30.6mg, p=0.0143) vs ↓15.05% placebo; HbA1c ↓1.10% (68mg) vs ↓0.31% placebo; 48.3% GI adverse events; 5 doses tested; 5-week treatment
How They Did This
Randomized, double-blind, placebo-controlled, multiple-ascending-dose Phase Ib/IIa trial. 60 patients with MASLD and T2DM randomized 10:2 to HEC88473 (5 dose levels: 5.1-68.0 mg) or placebo via weekly subcutaneous injection for 5 weeks. Primary outcomes included liver fat by MRI-PDFF, HbA1c, fasting and postprandial glucose, and lipid profiles. Safety assessed through adverse event monitoring.
Why This Research Matters
MASLD (formerly called NAFLD/NASH) affects roughly 30% of adults globally and has no widely approved pharmacological treatment beyond the recently approved resmetirom. The combination of GLP-1 and FGF21 activity is scientifically compelling because GLP-1 addresses appetite and blood sugar while FGF21 directly targets liver fat metabolism and lipid handling. Getting a 47% liver fat reduction in just 5 weeks is striking — most MASLD trials run 24-52 weeks. This drug's ability to simultaneously improve liver fat, blood sugar, and lipids could make it a single treatment for the cluster of metabolic problems that define metabolic syndrome.
The Bigger Picture
The metabolic drug landscape is rapidly evolving beyond single-target GLP-1 agonists toward multi-pathway approaches. Tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/glucagon) have shown that combining pathways produces greater effects. HEC88473 takes a different approach by pairing GLP-1 with FGF21 — specifically targeting liver fat metabolism. This positions it competitively for the massive MASLD market, where liver-specific efficacy is the key requirement. Published in the Journal of Hepatology (the field's top journal), these results from a Chinese pharmaceutical development program add to a wave of metabolic drugs emerging from China's biotech sector.
What This Study Doesn't Tell Us
This was a small Phase Ib/IIa trial (60 patients total, only 10 per dose group). The 5-week treatment duration is extremely short — longer studies are needed to confirm sustained efficacy and assess safety over months to years. No histological endpoints (liver biopsy) were assessed, which are considered the gold standard for MASLD trials. The 10:2 randomization ratio means only 2 placebo patients per cohort, limiting statistical power for safety comparisons. All patients were from China, so results may not generalize to other populations. The GI adverse event rate of 48.3% warrants monitoring at longer durations.
Questions This Raises
- ?Will the dramatic liver fat reductions seen at 5 weeks translate into improvements in liver fibrosis and inflammation on biopsy in longer trials?
- ?How does HEC88473 compare head-to-head with tirzepatide or resmetirom for liver fat reduction?
- ?Does the FGF21 component provide liver-specific benefits beyond what GLP-1 alone achieves, and would this justify the more complex molecule?
Trust & Context
- Key Stat:
- 47% liver fat reduction in 5 weeks The 30.6 mg dose achieved this relative reduction vs 15% with placebo, measured by MRI-PDFF — a remarkably rapid response
- Evidence Grade:
- Rated moderate because this is a well-designed randomized, double-blind, placebo-controlled human trial published in the Journal of Hepatology (top-tier). However, it's an early-phase trial (Ib/IIa) with only 60 patients, a very short 5-week duration, no histological endpoints, and small placebo groups per cohort.
- Study Age:
- Published in 2025, this represents the cutting edge of metabolic drug development. HEC88473 is in early clinical development, and larger Phase II/III trials would be expected if the company advances the program.
- Original Title:
- Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.
- Published In:
- Journal of hepatology, 82(6), 967-978 (2025)
- Authors:
- Xiang, Lin, Wang, Guixia(2), Zhuang, Yulei(2), Luo, Lin, Yan, Jiangyu, Zhang, Hong, Li, Xiaojiao, Xie, Can, He, Qingwei, Peng, Yuyu, Chen, Hong, Li, Qianqian, Li, Xiaoping, Guo, Linfeng, Lv, Guoyue, Ding, Yanhua
- Database ID:
- RPEP-14234
Evidence Hierarchy
Frequently Asked Questions
What's different about combining GLP-1 with FGF21 versus other combinations?
While tirzepatide combines GLP-1 with GIP (both gut hormones), HEC88473 pairs GLP-1 with FGF21 — a metabolic hormone that specifically targets liver fat, lipid metabolism, and insulin sensitivity. This makes it particularly suited for fatty liver disease, since FGF21 directly addresses the liver fat accumulation that defines the condition, while GLP-1 handles blood sugar and appetite.
Is a 47% reduction in liver fat clinically meaningful?
Yes, very much so. A 30% or greater relative reduction in liver fat (measured by MRI-PDFF) is widely considered clinically meaningful in MASLD research, as it correlates with improvements in liver inflammation and potentially fibrosis. Achieving 47% in just 5 weeks is exceptional — most drugs take 6-12 months to reach similar levels of fat reduction.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-14234APA
Xiang, Lin; Wang, Guixia; Zhuang, Yulei; Luo, Lin; Yan, Jiangyu; Zhang, Hong; Li, Xiaojiao; Xie, Can; He, Qingwei; Peng, Yuyu; Chen, Hong; Li, Qianqian; Li, Xiaoping; Guo, Linfeng; Lv, Guoyue; Ding, Yanhua. (2025). Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.. Journal of hepatology, 82(6), 967-978. https://doi.org/10.1016/j.jhep.2024.12.006
MLA
Xiang, Lin, et al. "Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.." Journal of hepatology, 2025. https://doi.org/10.1016/j.jhep.2024.12.006
RethinkPeptides
RethinkPeptides Research Database. "Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in ..." RPEP-14234. Retrieved from https://rethinkpeptides.com/research/xiang-2025-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.